N. Bishop u. a.: Risedronate in children with osteogenesis imperfecta: a randomised, double-blind, placebo-controlled trial. In: Lancet, 2013, 382, S. 1424–1432; doi:10.1016/S0140-6736(13)61091-0.
N. B. Watts, J. P. Brown, G. Cline: Risedronate on 2 consecutive days a month reduced vertebral fracture risk at 1year compared with historical placebo. In: Journal of Clinical Densitometry. Band13, Nr.1, 2010, S.56–62, doi:10.1016/j.jocd.2009.09.005, PMID 19942469.
T. Masud, M. McClung, P. Geusens: Reducing hip fracture risk with risedronate in elderly women with established osteoporosis. In: Clinical Interventions in Aging. Band4, 2009, S.445–449, PMID 19966913, PMC 2785868 (freier Volltext).
A. L. Langston, S. H. Ralston: Management of Paget's disease of bone. In: Rheumatology. Band43, Nr.8, August 2004, S.955–959, PMID 15187244.
N. B. Watts, J. P. Brown, G. Cline: Risedronate on 2 consecutive days a month reduced vertebral fracture risk at 1year compared with historical placebo. In: Journal of Clinical Densitometry. Band13, Nr.1, 2010, S.56–62, doi:10.1016/j.jocd.2009.09.005, PMID 19942469.
